Genocea Biosciences (GNCA) Misses Q1 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Genocea Biosciences (GNCA) Misses Q1 EPS by 5c

Genocea Reports First Quarter 2015 Financial Results

May 7, 2015 8:00 AM EDT

Phase 2 top-line data for GEN-003 for the treatment of genital herpes expected this quarter

$52 million financing completed in March 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the first quarter ended March 31, 2015.

"2015 is an important year for Genocea with significant clinical data readouts upcoming for both our lead programs. Top-line Phase 2 data for GEN-003, for the treatment of genital herpes, is expected this... More